HLA‒B*58:01 and skin reactions in pediatric hematology and oncology patients treated with allopurinol
Short-duration allopurinol exposure likely mitigates the risk of SCARs regardless of HLA-B*58:01 status. Routine HLA-B*58:01 testing may not be warranted in pediatric patients receiving brief allopurinol courses. However, larger studies are required to confirm these findings.
Authors
- Kleebsabai Sanpakit (ORCID: https://orcid.org/0000-0003-3452-1894)
- Jassada Buaboonnam (ORCID: https://orcid.org/0000-0002-5240-1071)
- Parisa Maneechai
- Cholada Ratanatharathron
Institutions
- Siriraj Hospital (TH)
- Mahidol University (TH)
Publication Details
- Journal
- Clinical and Experimental Pediatrics
- Published
- 2025-10-02
- DOI
- https://doi.org/10.3345/cep.2025.01032
- Citations
- 1
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Mahidol University
- Faculty of Medicine Siriraj Hospital, Mahidol University